Stoke Therapeutics Stock Analysis

STOK Stock  USD 13.57  1.26  10.24%   
Stoke Therapeutics is overvalued with Real Value of 12.34 and Target Price of 22.38. The main objective of Stoke Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Stoke Therapeutics is worth, separate from its market price. There are two main types of Stoke Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Stoke Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stoke Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.

Stoke Stock Analysis Notes

About 95.0% of the company shares are owned by institutional investors. The book value of Stoke Therapeutics was at this time reported as 6.41. The company has Price/Earnings To Growth (PEG) ratio of 0.27. Stoke Therapeutics had not issued any dividends in recent years. The entity had 1:9 split on the 6th of June 2019. Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases in the United States. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. Stoke Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 102 people. To find out more about Stoke Therapeutics contact the company at 781 430 8200 or learn more at https://www.stoketherapeutics.com.

Stoke Therapeutics Investment Alerts

Stoke Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 36.55 M. Net Loss for the year was (88.98 M) with profit before overhead, payroll, taxes, and interest of 190.91 M.
Stoke Therapeutics currently holds about 275.63 M in cash with (86.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.99.
Stoke Therapeutics has a poor financial position based on the latest SEC disclosures
Over 95.0% of the company shares are owned by institutional investors
Latest headline from thelincolnianonline.com: 42,100 Shares in Stoke Therapeutics, Inc. Bought by Kennondale Capital Management LLC

Stoke Therapeutics Upcoming and Recent Events

4th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Stoke Largest EPS Surprises

Earnings surprises can significantly impact Stoke Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-08-10
2020-06-30-0.35-0.39-0.0411 
2024-11-05
2024-09-30-0.53-0.46910.060911 
2023-11-07
2023-09-30-0.63-0.550.0812 
View All Earnings Estimates

Stoke Therapeutics Environmental, Social, and Governance (ESG) Scores

Stoke Therapeutics' ESG score is a quantitative measure that evaluates Stoke Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Stoke Therapeutics' operations that may have significant financial implications and affect Stoke Therapeutics' stock price as well as guide investors towards more socially responsible investments.

Stoke Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Goldman Sachs Group Inc2025-03-31
1.7 M
State Street Corp2025-03-31
1.6 M
Geode Capital Management, Llc2025-03-31
902 K
Checkpoint Capital Lp2025-03-31
730.7 K
Mpm Oncology Impact Management Lp2025-03-31
694 K
Dimensional Fund Advisors, Inc.2025-03-31
664.7 K
Granahan Investment Management Inc..2025-03-31
660.4 K
Assenagon Asset Management Sa2025-06-30
538 K
Bank Of America Corp2025-03-31
532.9 K
Skorpios Trust2025-03-31
6.9 M
Blackrock Inc2025-03-31
5.9 M
Note, although Stoke Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Stoke Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 740.88 M.

Stoke Profitablity

The company has Profit Margin (PM) of 0.26 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.7 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.7.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.33)(0.34)
Return On Capital Employed(0.44)(0.42)
Return On Assets(0.33)(0.34)
Return On Equity(0.39)(0.37)

Management Efficiency

Stoke Therapeutics has return on total asset (ROA) of 0.0781 % which means that it generated a profit of $0.0781 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.205 %, meaning that it created $0.205 on every $100 dollars invested by stockholders. Stoke Therapeutics' management efficiency ratios could be used to measure how well Stoke Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.34. Return On Capital Employed is expected to rise to -0.42 this year. At this time, Stoke Therapeutics' Total Current Liabilities is quite stable compared to the past year. Change To Liabilities is expected to rise to about 58.2 M this year, although the value of Liabilities And Stockholders Equity will most likely fall to about 224.3 M.
Last ReportedProjected for Next Year
Book Value Per Share 4.24  4.39 
Tangible Book Value Per Share 4.24  4.39 
Enterprise Value Over EBITDA(4.74)(4.98)
Price Book Value Ratio 2.60  2.73 
Enterprise Value Multiple(4.74)(4.98)
Price Fair Value 2.60  2.73 
Enterprise Value470.1 M604.3 M
The management team at Stoke Therapeutics has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Operating Margin
0.7015
Profit Margin
0.2633
Beta
1.142
Return On Assets
0.0781
Return On Equity
0.205

Technical Drivers

As of the 23rd of July, Stoke Therapeutics has the Risk Adjusted Performance of 0.2389, semi deviation of 2.74, and Coefficient Of Variation of 390.05. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Stoke Therapeutics, as well as the relationship between them.

Stoke Therapeutics Price Movement Analysis

The output start index for this execution was thirty-two with a total number of output elements of twenty-nine. The MESA Adaptive Moving Average indicator adapts to Stoke Therapeutics price movement based on the rate change of phase as measured by the Hilbert Transform Discriminator.

Stoke Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Stoke Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Stoke Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Stoke Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Levin Arthur A over three weeks ago
Acquisition by Levin Arthur A of 1210 shares of Stoke Therapeutics subject to Rule 16b-3
 
Ticho Barry over a month ago
Disposition of 6471 shares by Ticho Barry of Stoke Therapeutics at 10.0282 subject to Rule 16b-3
 
Ticho Barry over a month ago
Disposition of 1745 shares by Ticho Barry of Stoke Therapeutics at 10.0 subject to Rule 16b-3
 
Ticho Barry over two months ago
Disposition of 22790 shares by Ticho Barry of Stoke Therapeutics at 10.0282 subject to Rule 16b-3
 
Allan Jonathan over three months ago
Disposition of 2266 shares by Allan Jonathan of Stoke Therapeutics at 8.67 subject to Rule 16b-3
 
Allan Jonathan over three months ago
Acquisition by Allan Jonathan of 48000 shares of Stoke Therapeutics subject to Rule 16b-3
 
Kaye Edward M. Md over three months ago
Disposition of 35500 shares by Kaye Edward M. Md of Stoke Therapeutics subject to Rule 16b-3
 
Kaye Edward M. Md over three months ago
Disposition of 6170 shares by Kaye Edward M. Md of Stoke Therapeutics at 12.7775 subject to Rule 16b-3
 
Skorpios Trust over three months ago
Disposition of 3600000 shares by Skorpios Trust of Stoke Therapeutics at 11.6 subject to Rule 16b-3
 
Kaye Edward M. Md over six months ago
Acquisition by Kaye Edward M. Md of 35000 shares of Stoke Therapeutics at 0.6 subject to Rule 16b-3
 
Skorpios Trust over six months ago
Disposition of 2000000 shares by Skorpios Trust of Stoke Therapeutics at 11.5 subject to Rule 16b-3
 
Kaye Edward M. Md over six months ago
Disposition of 6786 shares by Kaye Edward M. Md of Stoke Therapeutics at 12.9912 subject to Rule 16b-3

Stoke Therapeutics Outstanding Bonds

Stoke Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Stoke Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Stoke bonds can be classified according to their maturity, which is the date when Stoke Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Stoke Therapeutics Predictive Daily Indicators

Stoke Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Stoke Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Stoke Therapeutics Corporate Filings

15th of July 2025
Other Reports
ViewVerify
8K
10th of July 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
9th of July 2025
Other Reports
ViewVerify
F4
2nd of July 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F3
23rd of June 2025
The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock
ViewVerify
6th of June 2025
Other Reports
ViewVerify
8K
4th of June 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
13th of May 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Stoke Therapeutics Forecast Models

Stoke Therapeutics' time-series forecasting models are one of many Stoke Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Stoke Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Stoke Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Stoke Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Stoke shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Stoke Therapeutics. By using and applying Stoke Stock analysis, traders can create a robust methodology for identifying Stoke entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(2.43)(2.56)
Operating Profit Margin(2.77)(2.91)
Net Loss(2.43)(2.56)
Gross Profit Margin 0.79  0.64 

Current Stoke Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Stoke analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Stoke analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
22.38Strong Buy10Odds
Stoke Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Stoke analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Stoke stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Stoke Therapeutics, talking to its executives and customers, or listening to Stoke conference calls.
Stoke Analyst Advice Details

Stoke Stock Analysis Indicators

Stoke Therapeutics stock analysis indicators help investors evaluate how Stoke Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Stoke Therapeutics shares will generate the highest return on investment. By understating and applying Stoke Therapeutics stock analysis, traders can identify Stoke Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow192 M
Common Stock Shares Outstanding54 M
Total Stockholder Equity229 M
Total Cashflows From Investing Activities-107.5 M
Property Plant And Equipment Net8.3 M
Cash And Short Term Investments216.9 M
Cash128 M
Accounts Payable2.5 M
Net Debt-125.7 M
50 Day M A11.0248
Total Current Liabilities40.1 M
Other Operating Expenses137.9 M
Non Current Assets Total38.8 M
Non Currrent Assets Other721 K
Stock Based Compensation27.5 M
When determining whether Stoke Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stoke Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Stoke Therapeutics Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stoke Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stoke Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.82
Revenue Per Share
3.354
Quarterly Revenue Growth
36.611
Return On Assets
0.0781
Return On Equity
0.205
The market value of Stoke Therapeutics is measured differently than its book value, which is the value of Stoke that is recorded on the company's balance sheet. Investors also form their own opinion of Stoke Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Stoke Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stoke Therapeutics' market value can be influenced by many factors that don't directly affect Stoke Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stoke Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.